Guides

eConsent regulations: What changed under FDA, ICH E6(R3), Part 11 and global regulations

Electronic informed consent, or eConsent, is no longer a novel approach to clinical research. Regulators around the world increasingly recognize electronic, remote and technology-enabled approaches to informed consent as part of modern clinical trial conduct.

But the regulatory environment has changed significantly.

The most important development is not a single new eConsent regulation. Instead, updates to Good Clinical Practice, electronic systems guidance and national clinical trial frameworks are changing how sponsors can design, document and manage informed consent.

ICH E6(R3) is central to that change. FDA issued E6(R3) as final guidance in September 2025, describing the revision as a modernization of GCP that embraces innovation in trial design, conduct and technology while emphasizing quality by design, participant protection and risk-based approaches. FDA subsequently withdrew its E6(R2) guidance in April 2026.

At the same time, regulatory developments in the United States, European Union, United Kingdom and Canada are providing clearer frameworks for electronic records, remote interactions and alternative ways of documenting consent.

For sponsors, CROs and clinical trial sites, the question is therefore changing. It is no longer simply, "Can informed consent be electronic?"

Increasingly, the question is: How can electronic informed consent be implemented in a way that protects participants, supports understanding, verifies identity where required, preserves reliable records and meets the requirements of every jurisdiction involved in a trial?

‍

Guides

How to improve comprehension and data quality with eConsent

Informed consent is the first data point in every clinical trial, and one of the easiest to get wrong. Discover how multimedia consent, embedded comprehension checks, and smarter re-consent workflows help sponsors turn eConsent into a real data quality lever, not just a digital signature.

‍

Guides

The right tool for the job: General AI vs clinical trial AI

AI
6 min

The clinical trials industry is at an operational inflection point. Despite decades of process refinement, drug development timelines have continued to lengthen, and manual workflows still account for a significant portion of skilled operator time across key trial functions. The emergence of large language model-based AI platforms has introduced a new variable into this equation, with multiple vendors now positioning their technology as a solution to these structural inefficiencies.

Two categories of vendors appear frequently in sponsor and CRO evaluations. The first are  general-purpose AI platforms, whose large language model capabilities have become some of the most widely benchmarked in the industry. The second are purpose-built clinical technology platforms with an established operational presence across decentralized and hybrid trial environments. 

Both have made substantive investments in life sciences AI in 2026. Their approaches, however, differ significantly in architecture, regulatory readiness, and deployment scope. This analysis examines those differences to help sponsors and CROs assess which type of platform is better suited to their operational requirements.

‍

Find the right AI vendor for your clinical trial stack. This 2026 guide covers integration-ready platforms for DCTs, EDC, eTMF, and more.
Guides

Which AI and agentic AI clinical trial vendors integrate best with existing systems?

Artificial intelligence is reshaping clinical trial operations in 2026. Sponsors and CROs are no longer evaluating standalone tools. They are choosing platforms that can connect with existing systems, automate complex workflows, and scale without disrupting ongoing studies. This guide breaks down the vendors best positioned to integrate with the clinical trial infrastructure you already have.

‍

Guides

Key criteria for evaluating AI and agentic AI clinical trial vendors

Artificial Intelligence is rapidly transforming clinical research. From patient recruitment and protocol design to medical writing and data review, AI-powered solutions are becoming embedded across the clinical development lifecycle. More recently, the emergence of Agentic AI (systems capable of planning, reasoning, and executing multi-step workflows with varying degrees of autonomy) has generated significant excitement throughout the industry.

However, not all AI solutions are created equal. While many vendors promise dramatic improvements in efficiency and productivity, clinical trial organizations operate in one of the most highly regulated environments in the world. Success depends not only on technical performance but also on compliance, validation, governance, security, and trust.

As sponsors, CROs, and technology teams evaluate potential AI partners, they need a framework that extends beyond traditional software procurement criteria. The following considerations can help organizations assess both AI and Agentic AI vendors and identify solutions that are truly ready for clinical research.

‍

Guides

eCOA, AI, and Agentic AI: A practical overview and guide

eCOA
6 min

Combining artificial intelligence (AI) and agentic AI with electronic Clinical Outcome Assessment (eCOA) systems fundamentally enhances how clinical trial data is collected, interpreted, and acted upon. At its core, eCOA captures structured data directly from patients, clinicians, or observers, such as symptom severity, quality of life, or functional outcomes. Modern platforms expand this further by supporting a full range of assessment types, including electronic patient-reported outcomes (ePRO), clinician-reported outcomes (eClinRO), observer-reported outcomes (eObsRO), and performance outcomes (ePerfO).

‍

Guides

eCOA vs ePRO: Understanding the differences in clinical trials

Digital data capture has become essential to modern clinical research. Sponsors and research organizations increasingly rely on electronic outcome assessment tools to collect high quality patient data, reduce manual errors, and improve regulatory compliance.

Two terms appear frequently in this space: eCOA (electronic Clinical Outcome Assessment) and ePRO (electronic Patient Reported Outcome).

These terms are closely related. However, they are not interchangeable.

‍

How to avoid common missteps when deploying eCOAs in clinical trials
Guides

Common missteps when deploying eCOAs in clinical trials

eCOA
6 min

Sometimes when teams deploy eCOA (electronic Clinical Outcome Assessment) in clinical trials, challenges can arise with operational planning, protocol design decisions, or workflow alignment. Below are some of the most common missteps observed across sponsors, CROs, and investigative sites.

1. Treating eCOA as a late-stage add-on

Many teams wait until protocol finalization or even after startup to plan eCOA implementation.

Why this causes problems

  • Instrument licensing or translations may not be ready
  • Build timelines get compressed
  • Protocol schedules may not align with electronic workflows

Best practice
Plan eCOA during protocol design, especially when selecting instruments and defining visit schedules. 

‍

Guides

How to successfully transition from paper COAs to eCOA

eCOA
6 min

Electronic clinical outcome assessment (eCOA) systems have reshaped how patient-reported outcome measures are collected and managed in clinical trials. Clinical operations leaders are under more pressure than ever to ensure that the migration from legacy paper instruments to digital platforms not only improves trial efficiency but also preserves data integrity, supports regulatory acceptance, and enhances participant experience.

The transition from paper to electronic capture represents a paradigm shift toward more efficient, accessible, and reliable data collection. Done well, eCOA strengthens evidence generation while reducing burden for participants and sites alike. Done poorly, it risks measurement bias, loss of comparability, and regulatory challenges.

In this article, clinical operations leaders will find evidence-based best practices for migrating and implementing patient-reported measures as part of eCOA strategies. These recommendations are rooted in published industry guidance and emerging scientific consensus, and they reflect the evolving landscape of digital assessment technologies.

‍

Guides

Common eCOA implementation pitfalls and how to avoid them

eCOA
6 min

The global eCOA (electronic clinical outcome assessment) solutions market was valued at over two billion dollars in 2025, and is projected to expand rapidly over the coming decade, driven by increased clinical trial activity, digital transformation efforts, and the integration of mobile, cloud, and AI-enabled tools for outcome measurement.

This growth reflects not just broader industry digitization, but an evolving expectation: that outcome data should be accurate, audit-ready through validated systems and controlled operational processes, and capable of supporting decentralized workflows.As more sponsors and CROs incorporate eCOA into their trial strategies and regulators continue to emphasize electronic data integrity the stakes of successful implementation have never been higher. 

Yet with greater adoption comes greater complexity: pitfalls around site burden, mid-study amendments, device logistics, and training gaps can undermine even the most advanced platforms if not thoughtfully addressed.

The good news? These common challenges can be anticipated and managed with practical, operationally aligned planning turning eCOA from a source of friction into a strategic advantage for trial success.

‍

Guides

Building blocks: Agentic AI is Transforming trial design, management, and outcomes

Discover how Agentic AI is revolutionizing clinical trials by optimizing efficiency, accelerating drug development, and improving patient access to therapies.

‍

See how Agent Studio can transform your trials.